Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

0.1289   0.006 (4.54%) 12-07 16:00
Open: 0.1212 Pre. Close: 0.1233
High: 0.1289 Low: 0.1131
Volume: 3,411,604 Market Cap: 16(M)

Technical analysis

as of: 2022-12-07 4:21:19 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.21     One year: 0.26
Support: Support1: 0.1    Support2: 0.08
Resistance: Resistance1: 0.18    Resistance2: 0.22
Pivot: 0.12
Moving Average: MA(5): 0.13     MA(20): 0.12
MA(100): 0.18     MA(250): 0.3
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 18.1     %D(3): 21
RSI: RSI(14): 48.9
52-week: High: 0.73  Low: 0.1
Average Vol(K): 3-Month: 5,259 (K)  10-Days: 16,467 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CRBP ] has closed below upper band by 48.1%. Bollinger Bands are 55.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.13 - 0.13 0.13 - 0.13
Low: 0.11 - 0.11 0.11 - 0.11
Close: 0.13 - 0.13 0.13 - 0.13

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Headline News

Thu, 01 Dec 2022
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session By Benzinga - Investing.com UK

Thu, 01 Dec 2022
Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Winner in the Biotechnology Industry? - InvestorsObserver

Wed, 30 Nov 2022
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.18% By Investing.com - Investing.com

Wed, 30 Nov 2022
Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Stock After it Is Higher By 81.82% in a Week? - InvestorsObserver

Wed, 30 Nov 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

Wed, 16 Nov 2022
Children – The Next Business Agenda: evolution of CRBP from principles to practice - Global Prime News

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 125 (M)
Shares Float 125 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 19 (%)
Shares Short 4,760 (K)
Shares Short P.Month 3,720 (K)

Stock Financials

EPS -0.32
EPS Est Next Qtl -0.19
EPS Est This Year -0.64
EPS Est Next Year -0.69
Book Value (p.s.) 0.34
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -22
Return on Equity (ttm) -69.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.29
Sales Per Share 0
EBITDA (p.s.) -0.27
Qtrly Earnings Growth 0
Operating Cash Flow -40 (M)
Levered Free Cash Flow -21 (M)

Stock Valuations

PE Ratio -0.42
PEG Ratio 0
Price to Book value 0.37
Price to Sales 0
Price to Cash Flow -0.41

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.